Peer-reviewed articles

Reduction of cardiovascular disease risk factors, such as obesity and LDL-cholesterol levels, is essential for primary prevention of cardiovascular events like heart attack or stroke. Patients who are unable or unwilling to tolerate statins for reduction of LDL-cholesterol need alternative lipid-lowering therapies to reduce their risk of cardiovascular events. Bempedoic acid is an adenosine triphosphate-citrate lyase that decreases cholesterol production by the liver and enhances LDL clearance. The Cholesterol Lowering via Bempedoic Acid (ECT1002), an ACL-Inhibiting Regimen (CLEAR) Outcomes trial was a double-blind, randomized study conducted at 1250 sites in 32 countries that compared daily bempedoic acid 180 mg to placebo in nearly 14,000 patients who were not able or willing to tolerate statins for lowering LDL-cholesterol.